328 related articles for article (PubMed ID: 37567938)
1. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors.
Sauer N; Janicka N; Szlasa W; Skinderowicz B; Kołodzińska K; Dwernicka W; Oślizło M; Kulbacka J; Novickij V; Karłowicz-Bodalska K
Cancer Immunol Immunother; 2023 Nov; 72(11):3405-3425. PubMed ID: 37567938
[TBL] [Abstract][Full Text] [Related]
2. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer.
Mohsenzadegan M; Bavandpour P; Nowroozi MR; Amini E; Kourosh-Arami M; Momeni SA; Bokaie S; Sharifi L
Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2131-2146. PubMed ID: 33745426
[TBL] [Abstract][Full Text] [Related]
3. Emerging immune checkpoints for cancer therapy.
Li X; Hu W; Zheng X; Zhang C; Du P; Zheng Z; Yang Y; Wu J; Ji M; Jiang J; Wu C
Acta Oncol; 2015 Nov; 54(10):1706-13. PubMed ID: 26361073
[TBL] [Abstract][Full Text] [Related]
4. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models.
Ma S; Tian Y; Peng J; Chen C; Peng X; Zhao F; Li Z; Li M; Zhao F; Sheng X; Zong R; Li Y; Zhang J; Yu M; Zhu Q; Tian X; Li Y; Neckenig MR; Liu H; Zhan P; Yue X; Wu Z; Gao L; Liang X; Liu X; Li C; Ma C
Sci Transl Med; 2023 Nov; 15(722):eadg6752. PubMed ID: 37967204
[TBL] [Abstract][Full Text] [Related]
5. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.
Du W; Yang M; Turner A; Xu C; Ferris RL; Huang J; Kane LP; Lu B
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28300768
[TBL] [Abstract][Full Text] [Related]
6. Tim-3 and its role in regulating anti-tumor immunity.
Das M; Zhu C; Kuchroo VK
Immunol Rev; 2017 Mar; 276(1):97-111. PubMed ID: 28258697
[TBL] [Abstract][Full Text] [Related]
7. TIM-3, a promising target for cancer immunotherapy.
He Y; Cao J; Zhao C; Li X; Zhou C; Hirsch FR
Onco Targets Ther; 2018; 11():7005-7009. PubMed ID: 30410357
[TBL] [Abstract][Full Text] [Related]
8. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L; Li Y; Tan J; Xu L; Li Y
J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
[TBL] [Abstract][Full Text] [Related]
9. New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors.
Gomes de Morais AL; Cerdá S; de Miguel M
Curr Oncol Rep; 2022 May; 24(5):651-658. PubMed ID: 35218498
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
11. TIM-3: An update on immunotherapy.
Zhao L; Cheng S; Fan L; Zhang B; Xu S
Int Immunopharmacol; 2021 Oct; 99():107933. PubMed ID: 34224993
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy.
Wu M; Wu A; Zhang X; Li Y; Li B; Jin S; Dong Q; Niu X; Zhang L; Zhou X; Du J; Wu Y; Zhai W; Zhou X; Qiu L; Gao Y; Zhao W
Biochem Pharmacol; 2023 Jun; 212():115583. PubMed ID: 37148978
[TBL] [Abstract][Full Text] [Related]
13. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of M6903, an antagonistic anti-TIM-3 monoclonal antibody.
Zhang D; Jiang F; Zaynagetdinov R; Huang H; Sood VD; Wang H; Zhao X; Jenkins MH; Ji Q; Wang Y; Nannemann DP; Musil D; Wesolowski J; Paoletti A; Bartholomew T; Derner MG; An Q; Iffland C; Halle JP
Oncoimmunology; 2020; 9(1):1744921. PubMed ID: 32313722
[TBL] [Abstract][Full Text] [Related]
15. Tim-3 and Tim-4 as the potential targets for antitumor therapy.
Cheng L; Ruan Z
Hum Vaccin Immunother; 2015; 11(10):2458-62. PubMed ID: 26211834
[TBL] [Abstract][Full Text] [Related]
16. Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
Natoli M; Hatje K; Gulati P; Junker F; Herzig P; Jiang Z; Davydov II; Germann M; Trüb M; Marbach D; Zwick A; Weber P; Seeber S; Wiese M; Lardinois D; Heinzelmann-Schwarz V; Rosenberg R; Tietze L; Mertz KD; Umaña P; Klein C; Codarri-Deak L; Kao H; Zippelius A
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319064
[TBL] [Abstract][Full Text] [Related]
17. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
18. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
[No Abstract] [Full Text] [Related]
19. Prospects of TIM-3 as a Promising Diagnostic and Prognostic Biomarker for Cancer Patients.
Chen F; Chen Q; Zhong L; Zhao Y
Discov Med; 2021; 31(162):15-20. PubMed ID: 34965367
[TBL] [Abstract][Full Text] [Related]
20. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]